SIGN UP
LOG IN
UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study. Trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's. Cerevel's drug met the main goal of a late stage trial.
Reuters · 1h ago
UPDATE 2-Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial. Drug tested as an add-on therapy to levodopa. The disease affects about 1 million people in the United States. AbbVie agreed to buy Cerevel Therapeutics in December for $8.7 billion.
Reuters · 1h ago
CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATED
Reuters · 1h ago
BUZZ-Moody's says pharma outlook turns 'positive' on GLP-1 drug push
Moody's says outlook for U.S. Pharmaceutical credit to "positive" from "stable" on GLP-1 and other blockbuster drugs push. Positive outlook reflects expectations of 4%-6% annual core earnings growth over the 12-18 months. Industry growth will benefit from rising use of blockbuster drugs.
Reuters · 03/14 14:35
UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports
AbbVie looking to sell at least $13 billion of corporate bonds to fund M&A, Bloomberg reports. The sale is expected to be announced as soon as Thursday, the report says. The drugmaker is looking to fund its acquisitions of ImmunoGen and Cerevel Therapeutics.
Reuters · 02/21 23:41
Abbvie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports
Abbvie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports. The company is looking to sell bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics. AbbVie to sell corporate bonds to raise money to fund acquisitions, Bloomberg says.
Reuters · 02/21 23:02
Cerevel Therapeutics Holdings Inc <CERE.OQ> expected to post a loss of 59 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 59 cents a share. The company is expected to show change in quarterly revenue when it reports results on February 20. Average analyst rating on the shares is "hold" and the median 12-month price target is $45.
Reuters · 02/16 13:55
UPDATE 1-AbbVie profit beats on better-than-expected Humira, Botox sales
AbbVie profit beats on better-than-expected Humira, Botox sales. Humira's sales fell 41% to $3.30 billion in the fourth quarter, but beat estimates. The company reported a quarterly adjusted profit of $2.79 per share.
Reuters · 02/02 13:16
Webull offers CEREVEL THERAPEU stock information, including NASDAQ: CEREW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEREW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CEREW stock methods without spending real money on the virtual paper trading platform.